Neuphoria Therapeutics Inc. Common Stock (NEUP)

Price$4.49

Value ScoreB

Growth ScoreD

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-8.59%

Price vs S&P 500 (4W)-15.43%

VGM Score43.31

Market Capitalization$24.27M

All Metrics

P/CF (Annual)314.33x

Book Value / Share (Quarterly)$5.47

P/TBV (Annual)0.94x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)696.24%

Cash Flow / Share (Quarterly)$-3.19

Price vs S&P 500 (YTD)7.56%

Net Profit Margin (TTM)59.50%

EPS (TTM)$-8.77

10-Day Avg Trading Volume0.07M

EPS Excl Extra (TTM)$-8.77

EPS (Annual)$-0.23

ROI (Annual)-1.94%

Cash / Share (Quarterly)$3.62

ROA (Last FY)-1.29%

Revenue Growth TTM (YoY)-27.00%

EBITD / Share (TTM)$-4.57

Operating Margin (TTM)52.82%

Cash Flow / Share (Annual)$0.04

P/B Ratio0.82x

P/B Ratio (Quarterly)0.75x

Net Income / Employee (Annual)$-52,900

Net Interest Coverage (TTM)-2.37x

ROA (TTM)-54.76%

EPS Incl Extra (Annual)$-0.23

Current Ratio (Annual)3.56x

Quick Ratio (Quarterly)13.91x

3-Month Avg Trading Volume0.05M

52-Week Price Return-37.20%

EV / Free Cash Flow (Annual)62.95x

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$4.67

P/S Ratio (Annual)1.55x

Asset Turnover (Annual)0.55x

52-Week High$21.40

EPS Excl Extra (Annual)$-0.23

26-Week Price Return-0.66%

Quick Ratio (Annual)3.39x

13-Week Price Return-1.10%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)14.31x

Enterprise Value$4.86M

Asset Turnover (TTM)0.64x

Revenue / Employee (Annual)$2,235,600

Pretax Margin (Annual)-5.35%

Cash / Share (Annual)$7.18

3-Month Return Std Dev51.85%

Net Income / Employee (TTM)$-2,490,200

ROE (Last FY)-1.95%

Net Interest Coverage (Annual)-9.14x

EPS Basic Excl Extra (Annual)$-0.23

Receivables Turnover (TTM)0.76x

EV / Free Cash Flow (TTM)13.82x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-8.77

Receivables Turnover (Annual)2.60x

ROI (TTM)-76.81%

P/S Ratio (TTM)1.55x

Revenue / Share (Annual)$9.64

Tangible BV / Share (Annual)$7.18

Price vs S&P 500 (52W)-61.57%

Year-to-Date Return15.72%

5-Day Price Return-15.28%

EPS Normalized (Annual)$-0.23

ROA (5Y Avg)-36.63%

Net Profit Margin (Annual)-2.36%

Month-to-Date Return-15.44%

EBITD / Share (Annual)$-0.29

Operating Margin (Annual)-7.21%

P/CF (TTM)32.84x

EPS Basic Excl Extra (TTM)$-8.77

P/TBV (Quarterly)0.87x

P/B Ratio (Annual)0.70x

Pretax Margin (TTM)59.05%

Book Value / Share (Annual)$9.61

Price vs S&P 500 (13W)-9.36%

Beta0.76x

P/FCF (Annual)314.33x

Revenue / Share (TTM)$0.00

ROE (TTM)-76.93%

52-Week Low$3.65

vGradeB

gGradeD

mGradeC

vgmGradeC

Show chart for

Earnings Surprise History

Q3 26-0.09est. -0.99

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.00

4.13

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
NEUPNeuphoria Therapeutics Inc. Common Stock	B	D	C	$4.49
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Neuphoria Therapeutics is a clinical-stage biotechnology company developing treatments for neuropsychiatric disorders. Its lead candidate, BNC 210, is an oral selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor in development for acute social anxiety disorder and chronic post-traumatic stress disorder. The company focuses on allosteric ion channel modulators targeting central nervous system disorders with significant unmet medical needs.